Seven Fleet Capital Management LP Buys Shares of 167,223 Taysha Gene Therapies, Inc. $TSHA

Seven Fleet Capital Management LP acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 167,223 shares of the company’s stock, valued at approximately $920,000. Taysha Gene Therapies accounts for 0.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 26th biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Marex Group plc bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies during the 2nd quarter valued at $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at $40,000. Tower Research Capital LLC TRC increased its position in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after buying an additional 4,607 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $6.42 on Friday. The company’s fifty day moving average is $5.90 and its two-hundred day moving average is $5.22. The company has a market cap of $1.84 billion, a P/E ratio of -16.89 and a beta of 1.19. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities analysts expect that Taysha Gene Therapies, Inc. will post -0.5 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TSHA. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Needham & Company LLC lifted their target price on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Canaccord Genuity Group upped their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $11.64.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.